ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Asston Pharmaceuticals schedules a November 12, 2026 board meeting to approve half-year unaudited financial statements. Agenda items are proposed until the meeting is held.
Asston Pharmaceuticals Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. It also disclosed a recent preferential allotment of 24.10 lakh equity shares.
Asston Pharmaceuticals Limited announced a change in the company's registered office address within the same city, effective from 15th October 2026.
The company submitted a revised shareholding pattern following the allotment of 24,10,431 equity shares through a preferential allotment dated September 5, 2026.
Asston Pharmaceuticals Limited has scheduled a board meeting on 13 October 2026 to consider other business matters. The company's trading window remains closed until 17 October 2026.
Asston Pharmaceuticals Limited has appointed M/s. Panchal S K & Associates as its Statutory Auditor for a five-year term. The appointment is effective from April 1, 2026.
Asston Pharmaceuticals Limited concluded its 7th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including adoption of financial statements and director remuneration increases.
Asston Pharmaceuticals Ltd submitted its quarterly shareholding pattern disclosure, detailing the shareholding status of promoters and public shareholders for the period ended March 2026.
Asston Pharmaceuticals has submitted its 7th Annual Report for the financial year 2025-26. The report provides a comprehensive overview of the company's annual financial performance.
Asston Pharmaceuticals Limited announced its Annual General Meeting scheduled for September 29, 2026. The agenda includes adopting financial statements, appointing auditors, and revising remuneration for key managerial personnel.
Asston Pharmaceuticals allotted 24,10,431 equity shares at Rs. 115 per share via preferential allotment, raising Rs. 27.72 Crore. This increases the company's paid-up equity share capital.
Asston Pharmaceuticals announced the outcome of its board meeting, including auditor appointments, director re-appointment, and upcoming AGM scheduling. The board also proposed remuneration increases for directors.
Prakruti R Pali acquired 2,40,000 shares of Asston Pharmaceuticals Ltd through an open market purchase. Post-acquisition stake is 5.33%.
Asston Pharmaceuticals will hold a board meeting on September 4, 2026, to discuss auditor appointment, director remuneration increases, and the upcoming Annual General Meeting.
Asston Pharmaceuticals held an EGM on July 31, 2026. Shareholders approved a special resolution to issue equity shares on a preferential basis.
Asston Pharmaceuticals convened an EGM for July 31, 2026. Shareholders will vote on a special resolution to issue equity shares on a preferential basis.
Asston Pharmaceuticals convened an EGM for July 31, 2026. The agenda includes a Rs. 27.72 Crore preferential allotment of 24.10 lakh equity shares.
Asston Pharmaceuticals approved a Rs.27.72 Crore preferential share issue to non-promoters. An EGM is scheduled for July 31, 2026, for shareholder approval.
Asston Pharmaceuticals scheduled a board meeting for July 2, 2026. The board will consider raising funds via preferential issues.
Asston Pharmaceuticals Ltd reported revenue from operations of ₹10.1 Cr (+11.0% YoY) and net profit of ₹0.5 Cr (-75.0% YoY) for H2 FY26.
Asston Pharmaceuticals approved audited financial results for FY26, reporting a total income of ₹31.58 Crore. The board meeting concluded at 07:10 P.M. on May 29, 2026.
Asston Pharmaceuticals scheduled a board meeting on May 29, 2026, to approve audited FY26 financial results. This routine regulatory notice precedes official performance disclosures.